Delivery Order HHSN261201200021I-HHSN26100006

This is a contract awarded by the National Cancer Institute (NCI), an institute within the National Institutes of Health (NIH), to The University of Texas MD Anderson Cancer Center. The $2,186,264.78 contract is for a randomized, double-blind, placebo-controlled study of a topical breast cancer prevention agent, 4-hydroxytamoxifen gel, in women with dense breast tissue. This contract was issued under the NCI's Cancer Prevention Agent Development Program, which supports early phase clinical...

This is a delivery order contract awarded by the National Cancer Institute (NCI) to The University of Texas MD Anderson Cancer Center (MD Anderson) valued at $658,199.33. The contract is for a phase I dose escalation study of a topical cancer prevention agent, bexarotene, in women at high risk for breast cancer. It is part of the NCI's Cancer Prevention Agent Development Program, an early-phase clinical research initiative. The contract does not have a set-aside designation. MD Anderson is a...

The National Cancer Institute awarded a $1.89 million cost-plus-fixed-fee delivery order to IIT Research Institute (IITRI) on September 16, 2024, for toxicology studies in rats and dogs involving the experimental compound AIT-102. The work will be performed in Chicago, Illinois, with a completion date of June 30, 2026. This delivery order was issued under one of IITRI's existing indefinite delivery/indefinite quantity (IDIQ) contract vehicles with NCI—specifically the $149.995 million PREVENT...

This is a $1,162,921.53 firm-fixed-price delivery order contract awarded by the National Cancer Institute (NCI) to The University of Texas M.D. Anderson Cancer Center (MD Anderson) for the "Evaluation of Real-Time Metabolic Imaging Biomarkers for Detection of Pancreatic Premalignant Lesions". The contract is part of the larger "PREVENT Preclinical Drug Development Program: Preclinical Efficacy & Intermediate Biomarkers" indefinite delivery, indefinite quantity (IDIQ)...

This is a $35,600 firm fixed price purchase order contract awarded by the National Institutes of Health (NIH) National Center for Advancing Translational Sciences (NCATS) to Pharmaron, Inc., a minority-owned for-profit organization, to conduct a mouse study evaluating NNMT inhibitors in high grade serous ovarian cancer. The work, which has a 12-month period of performance, involves formulating compounds, developing a mouse model, conducting efficacy studies, and analyzing samples. No set-aside...

This is a delivery order awarded by the National Cancer Institute (NCI) to The University of Texas MD Anderson Cancer Center (MD Anderson) under the "PREVENT Preclinical Drug Development Program (PREVENT)" Indefinite Delivery Contract (IDC). The delivery order, valued at $840,820.00, is for a project titled "TARGETING STAT3 TO PREVENT HEPATOCELLULAR CARCINOMA (HCC) ASSOCIATED WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH)". The project is focused on preclinical efficacy and...

The Institute For Cancer Research, a non-profit subsidiary of Temple University, has been awarded a $884,185.34 firm fixed price delivery order against the National Cancer Institute's PREVENT Cancer Program multiple award indefinite delivery contract vehicle. This delivery order focuses on continued evaluation of candidate chemopreventive and immunopreventive regimens in support of the PRECLINICAL PREVENT CANCER PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMARKERS through January...

This is a delivery order awarded by the Department of Health and Human Services National Institutes of Health National Cancer Institute to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The award is part of the PREVENT Cancer Program (PREVENT), which supports preclinical research on preventing triple-negative breast cancer. The $774,513.14 firm-fixed-price task order covers research targeted at the RXR pathway for the prevention of...

The National Cancer Institute awarded The Institute For Cancer Research a firm fixed-price delivery order valued at $1.24M under the PREVENT Preclinical Drug Development Program, with performance scheduled to conclude on November 17, 2026. This task order, titled "Next Generation GP130/IL-6/STAT3 Inhibitors for the Prevention of Colitis-Associated Colorectal Cancer," was awarded on May 18, 2022, without set-aside designation. The Institute For Cancer Research, a non-profit subsidiary...

The National Cancer Institute awarded a Firm Fixed Price Delivery Order contract to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System, valued at $1,121,090.00. The contract is part of the PREVENT Preclinical Drug Development Program and supports preclinical efficacy and intermediate endpoint biomarker studies targeting the PARP pathway for the prevention of breast cancer. The contract has a period of performance through May 31, 2026 and is not set...